Quick answer
Yes, compounded semaglutide is legal in 2026. It requires a physician prescription and must come from a licensed compounding pharmacy. 503B outsourcing facilities — the highest regulatory tier, FDA-inspected — can continue compounding semaglutide legally. Marrow sources exclusively from FDA-registered 503B facilities.
Regulatory Status 2026
Is Compounded Semaglutide Legal in 2026?
The short answer is yes — with important nuance. Here is a plain-English breakdown of the current regulatory status and what it means for patients.
What happened with the FDA and compounded semaglutide
In 2022–2023, semaglutide was placed on the FDA drug shortage list due to overwhelming demand for Ozempic and Wegovy. Being on the shortage list created a specific legal pathway for compounding pharmacies to produce semaglutide — even 503A pharmacies that normally could not.
In late 2024, the FDA removed semaglutide from its shortage list after Novo Nordisk increased supply. This changed the rules for 503A pharmacies significantly — they face more restrictions under non-shortage conditions. The FDA also sent warning letters to some providers making unapproved claims or not following proper prescribing protocols.
However, 503B outsourcing facilities operate under different rules. These federally registered, FDA-inspected pharmacies can continue compounding semaglutide when prescribed by licensed physicians with documented patient need. This is the tier Marrow uses.
503A vs 503B: the key distinction
| Factor | 503A | 503B (Marrow) |
|---|---|---|
| Regulation | State pharmacy boards | FDA (federally) |
| Inspection | State inspection | FDA inspection, pharmaceutical-grade |
| Semaglutide status | More restricted post-shortage removal | Can continue under physician prescription |
| Who uses it | Most telehealth companies | Marrow · Hospital systems |
What the FDA warning letters actually targeted
The FDA warning letters in 2025–2026 targeted specific compliance failures — not compounded semaglutide itself. The violations included marketing compounded drugs as equivalent to FDA-approved products, compounding without valid physician prescriptions, making unsupported efficacy claims, and selling direct-to-consumer without physician oversight.
These violations are about how compounding is done, not whether compounding is legal. A compliant provider with proper physician oversight, 503B sourcing, and accurate claims operates legally.
Frequently asked questions
Is compounded semaglutide legal in 2026?
Yes, compounded semaglutide remains available in 2026 through licensed telehealth providers and physician prescription. Compounding pharmacies can legally compound semaglutide when prescribed by a licensed physician for a specific patient with documented medical need.
Did the FDA ban compounded semaglutide?
The FDA removed semaglutide from its shortage list in late 2024, which changed the regulatory landscape. 503A compounding pharmacies have more restrictions, but 503B outsourcing facilities (the highest-regulated tier) can continue compounding under specific conditions. Marrow sources from 503B facilities.
What is a 503B pharmacy and why does it matter?
503B outsourcing facilities are FDA-registered, federally inspected compounding pharmacies that meet pharmaceutical-grade sterility standards. They can legally produce compounded medications for patient populations, not just individual prescriptions. This is the regulatory tier that allows continued compounding of semaglutide.
How is Marrow's semaglutide different from the ones getting FDA warning letters?
The FDA has issued warning letters to 503A pharmacies and direct-to-consumer sellers making unapproved claims or not following proper prescribing protocols. Marrow sources from FDA-registered 503B facilities, requires physician prescriptions for every patient, and complies with applicable telehealth regulations.
Will compounded semaglutide still be available in 2026 and beyond?
The regulatory environment continues to evolve. 503B facilities remain the most legally defensible source for compounded semaglutide. Marrow monitors regulatory developments closely and will communicate directly with patients about any changes that affect their treatment.
Get compounded semaglutide from a 503B pharmacy
Licensed physicians. FDA-registered 503B pharmacy. Physician review in 24 hours.
Start your intake →